Antisense RNA for treating cancer and inhibition of metastasis and vectors for antisense sequestration

Inventors

Bonci, Desiree • De Maria, Ruggero

Assignees

Istituto Superiore di Sanità • Instituto Superiore di Sanita

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-9702880-B2

Patent

Publication Date

2017-07-11

Expiration Date


Abstract

Provided is the use of antisense RNA and methods for the treatment, diagnosis and prophylaxis of cancer comprising administering said antisense RNA, particularly miRs 15 and 16 to a patient in need thereof.

Core Innovation

The invention relates to antisense microRNA therapy for cancer, including diagnosing progression of prostate cancer to an advanced stage and treating cancerous prostate tissue or prostate tumor. The disclosed approach centers on miR 15a and miR 16-1 (miR 15/16), including antisense RNA forms complementary to all or part of the 3′ untranslated region of Cyclin D1, Wnt3a, and/or bFGF protein mRNA. The disclosed methods connect miR 15/16 expression status with prostate cancer stage assessment and downstream regulation.

For diagnosis, the invention detects levels of expression of miR 15a and miR 16-1 in cells from cancerous prostate tissue or a cancerous prostate tumor. Down-regulation of miR 15a and miR 16-1 is used as a diagnostic criterion for progression of prostate cancer to an advanced stage relative to normal prostate cells, primary prostate tumor cells, or benign prostate tissue. Detection is performed using Northern hybridization or in situ hybridization with miR 15a-specific probes and miR 16-1-specific probes.

For treatment, the invention administers antisense RNA to a patient in need thereof or causes antisense RNA to be expressed in the patient. The antisense RNA is either miR 15 and miR 16-1 or is complementary to all or part of the 3′ untranslated region of Cyclin D1, Wnt3a, and/or bFGF protein mRNA. The disclosed biological support describes that miR 15a/miR 16 are downregulated in a majority of analyzed prostate tumors, and that restoring miR 15a/miR 16 induces growth arrest and apoptosis with tumor regression.

Claims Coverage

The partial content provides two independent claims. Together, these claims cover diagnosing advanced-stage progression in prostate cancer based on down-regulation of miR 15a and miR 16-1 using specified probe methods, and diagnosing the same progression and treating prostate cancer using antisense RNA directed to miR 15/16 and/or 3′UTRs of Cyclin D1, Wnt3a, and/or bFGF protein mRNA.

Diagnosing advanced-stage prostate cancer by detecting miR 15a and miR 16-1 down-regulation

A method diagnosing progression of a cancerous prostate tissue or tumor to an advanced stage by detecting levels of expression of miR 15a and miR 16-1 in cells from the cancerous prostate tissue or cancerous prostate tumor, where progression is diagnosed when miR 15a and miR 16-1 are down-regulated compared to normal prostate cells, primary prostate tumor cells, or benign prostate tissue; detection is performed by Northern hybridization or in situ hybridization using miR 15a and miR 16-1 specific probes.

Diagnosing advanced-stage prostate cancer and treating with antisense RNA to miR 15/16 or 3′UTRs of Cyclin D1, Wnt3a, and/or bFGF

A method diagnosing progression of cancerous prostate tissue or prostate tumor to an advanced stage and treating the cancerous prostate tissue or prostate tumor by detecting miR 15a and miR 16-1 as down-regulated in cancerous prostate tumor cells or tissue compared to normal, primary, or benign tissue, wherein detection comprises quantitative real-time polymerase chain reaction or Northern hybridization or in situ hybridization using primers or probes for miR 15a and miR 16-1; and administering antisense RNA to a patient in need thereof or causing antisense RNA to be expressed, wherein the antisense RNA is miR 15 and miR 16-1 or is complementary to all or part of the 3′ untranslated region of Cyclin D1, Wnt3a, and/or bFGF protein mRNA.

Across the independent claims, the core claim coverage is directed to using down-regulation of miR 15a and miR 16-1 for diagnosing advanced-stage progression in prostate cancer, and in combination with antisense RNA administration targeting miR 15/16 and/or 3′UTRs of Cyclin D1, Wnt3a, and/or bFGF mRNA for treating prostate cancer.

Stated Advantages

Allows diagnosis of progression of prostate cancer to an advanced stage when miR 15a and miR 16-1 are down-regulated.

Enables treatment of cancerous prostate tissue or prostate tumor using antisense RNA targeting miR 15 and miR 16-1 or complementary 3′UTR sequences of Cyclin D1, Wnt3a, and/or bFGF protein mRNA.

Documented Applications

Diagnosing progression of a cancerous prostate tissue or tumor to an advanced stage by detecting miR 15a and miR 16-1 down-regulation using Northern hybridization or in situ hybridization with miR-specific probes.

Diagnosing advanced-stage prostate cancer progression and treating cancerous prostate tissue or prostate tumor by administering antisense RNA to a patient in need thereof.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.